A key step in the drug development process is to predict information on safety, efficacy and mechanisms of action of a candidate molecule as early as possible in the pipeline (drug screening). To accomplish this aim, physiological and pathological pre-clinical models that closely approximate the human body are required. The limited capabilities of most of the existing pre-clinical screening tools, unable to meet the physiological relevance required to screen out failing drug candidates, reflect in the current weak performances of drug discovery: high attrition rates indeed affect the process of taking drugs from lab to market. Despite emerging new technologies exist with potential for advancing the field of in vitro modelling, their successfully implementation in the drug discovery pipeline to make it more efficient is still challenging. This is also imputable to a lack of structured dialogue between academic technology providers, market-oriented and regulatory-aware CROs, Biotechs and Pharma companies, which finally affects the research, training and development pipeline. SINERGIA aims at integrating a training network where academic and non-academic actors contribute to unravel the potential of the synergistic and rational use of four key bioengineering technologies. In particular, SINERGIA features academic leading experts of i) organs-on-chip and microfabrication technologies; ii) bioreactor and tissue engineering; iii) 3D Bioprinting; iv) induced-pluripotent human stem cells. These techniques are deployed to CROs and Biotech Consortium members that will ensure rational development, exploitation, validation and compliancy with regulatory and industrial aspects. Ultimately, this concerted action will lead to advanced models of human physiology and diseases to be introduced in preclinical stages of an innovative and improved drug discovery pipeline.